Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11382828 | 0.89 | MAPT (0.50) | MAPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL20756330 | 0.86 | KDM4E (0.39) | CA5AMAPTSMN1; SMN2L3MBTL1ATM | |
| SCHEMBL23490292 | 0.84 | MEN1 (0.38) | CA5AMAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL13545179 | 0.82 | MEN1 (0.49) | MAPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL21029640 | 0.82 | POLB (0.36) | CA5AKMT2AMEN1HPGDLMNA | |
| SCHEMBL669554 | 0.81 | CA5A (0.67) | CA5AMAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL8418226 | 0.80 | MEN1 (0.58) | CA5AMAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL18632252 | 0.80 | MAPT (0.43) | MAPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL8282094 | 0.80 | MAPT (0.59) | MAPTSMN1; SMN2L3MBTL1KMT2AATM | |
| SCHEMBL22548930 | 0.78 | MAPT (0.44) | MAPTSMN1; SMN2L3MBTL1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408840-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder | ARDELYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160067242-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20150190389-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER | ARDELYX, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8969377-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140107074-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150190389-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER | SLC9A1, SLC9A2, SLC10A2 | CA5A 1402/4885MAPT 4590/4885SMN1; SMN2 3491/4885 |
| US-20160067242-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | CA5A 623/4885MAPT 4323/4885SMN1; SMN2 4781/4885 |
| US-20140107074-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A2, SLC9A1, SLC9A2 | CA5A 1713/4885MAPT 4756/4885SMN1; SMN2 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.